EBV (VCA)- IgM antibody to Viral capsid antigen(VCA)

Bacterial/ Viral

Report in 48Hrs

At Home

No Fasting Required

Details

Detects Epstein-Barr virus antibodies.

₹2,146₹3,066

30% OFF

EBV (VCA)-IgM Antibody to Viral Capsid Antigen (VCA) - Comprehensive Medical Test Guide

Why is it done?
- Test Purpose: Detects IgM antibodies produced by the immune system in response to initial Epstein-Barr virus (EBV) infection, indicating acute or recent infection with EBV
- Primary Indications: Diagnosis of acute infectious mononucleosis (IM) or primary EBV infection; differentiation between acute and past infection; evaluation of patients with clinical symptoms consistent with EBV infection
- Typical Timing: Performed during acute illness presentation with fever, sore throat, lymphadenopathy, and fatigue; most useful when symptoms have been present for 1-2 weeks; typically ordered as part of initial diagnostic workup for suspected mononucleosis
- Clinical Circumstances: Pediatric and adult patients with symptoms suggestive of acute EBV infection; immunocompromised patients with EBV-related complications; evaluation of atypical lymphocytosis; assessment of fever of unknown origin
Normal Range
- Reference Range: Negative or <1.1 (Interpretation varies by laboratory; typically reported as Negative, Positive, or as numerical ratios/titers)
- Units of Measurement: Index (often expressed as a ratio or titer); some labs use numerical values with cutoffs: <0.8 negative, 0.8-1.0 equivocal/borderline, >1.1 positive
- Normal Result Interpretation: Negative result indicates absence of recent/acute EBV infection; suggests either no current infection, past infection only, or infection occurring outside the window of IgM detection (typically 1-3 months)
- Abnormal Result Interpretation: Positive result indicates acute or recent primary EBV infection; highly suggestive of current or very recent infection (typically within 1-3 months); requires clinical correlation with symptoms
- Borderline/Equivocal Values: Index values between 0.8-1.0 are considered equivocal; may require repeat testing in 1-2 weeks or additional serological testing for confirmation; clinical context is essential for interpretation
Interpretation
- Positive IgM VCA Result: Strongly indicates acute primary EBV infection; typically appears early in infection (within first 1-2 weeks of symptom onset) and persists for 3-6 months; peak levels usually occur around 4 weeks; confirms active viral replication
- Negative IgM VCA Result: Rules out acute infection in symptomatic patients; indicates either past infection (immune), no infection, or infection beyond the IgM window; should be correlated with IgG VCA and EBNA antibody results for complete interpretation
- Combined with Other EBV Serology: VCA-IgM alone is insufficient; should be interpreted with VCA-IgG and EBNA results to establish stage of infection: IgM+/IgG-/EBNA- = acute infection; IgM-/IgG+/EBNA+ = past infection or latent phase
- Factors Affecting Results: Timing of testing relative to symptom onset; immunocompromised status (may show weakened or absent response); prior EBV infection (IgM typically absent); laboratory variation in test methodology and cutoff values
- Clinical Significance: Positive IgM-VCA confirms diagnosis of acute infectious mononucleosis; differentiates from other viral illnesses causing similar symptoms; particularly useful in early symptomatic phase; guides clinical management decisions
- Serial Testing Pattern: IgM levels rise early and peak around week 4, then gradually decline; persistent elevated IgM beyond 6 months is unusual and may suggest chronic active EBV or reactivation; serial testing helps confirm acute infection if initial results are equivocal
Associated Organs
- Primary Organ System: Lymphoid system including lymph nodes, spleen, and thymus; secondarily involves immune system (B and T lymphocytes); respiratory tract (throat/pharynx); and hematopoietic system
- Associated Medical Conditions: Acute infectious mononucleosis (primary manifestation); fever, pharyngitis, and lymphadenopathy; splenomegaly and hepatomegaly; atypical lymphocytosis with elevated WBC counts
- Diseases Diagnosed or Monitored: Primary acute EBV infection; infectious mononucleosis; differential diagnosis of viral pharyngitis; chronic active EBV infection (CAEBV); EBV-associated lymphoproliferative disorders in immunocompromised patients
- Associated Complications: Severe pharyngitis with airway obstruction; splenic rupture (rare); hepatitis with jaundice; neurological complications including meningitis and encephalitis; myocarditis; secondary bacterial superinfection of throat
- High-Risk Populations: Young adults and adolescents; immunocompromised individuals (HIV/AIDS, transplant recipients); patients on chronic immunosuppressive therapy; patients with congenital immune deficiencies
- EBV Latency and Reactivation: Virus persists in B lymphocytes after acute infection; establishes lifelong latency; can reactivate in immunosuppressed states, causing severe disease; associated with Burkitt lymphoma, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disorder
Follow-up Tests
- EBV Serology Panel Completion: VCA-IgG (detects past or current infection, remains positive lifelong); EBNA antibody (indicates past infection and latency, appears after acute phase); together with IgM-VCA, provides complete serological profile
- Complete Blood Count (CBC): Assesses degree of lymphocytosis and atypical lymphocyte percentage; evaluates platelet count (thrombocytopenia can occur); monitors white blood cell differential
- Liver Function Tests: AST, ALT, bilirubin to assess for hepatitis; approximately 80% of IM patients have elevated transaminases; helps identify hepatic involvement
- Monospot Test (Heterophile Antibody Test): Rapid screening test for infectious mononucleosis; less specific but faster than EBV serology; positive in most acute IM cases; may be negative early in infection
- EBV PCR/Viral Load: Quantifies circulating EBV DNA; useful in immunocompromised patients; monitors treatment response; helps detect reactivation or chronic active EBV
- Throat Culture: Rule out group A streptococcal pharyngitis (bacterial superinfection); important for guiding antibiotic therapy decisions
- Abdominal Ultrasound: Evaluates for splenomegaly and hepatomegaly; performed if abdominal pain present; baseline if splenic rupture risk assessment needed
- Repeat Testing: Recommended if initial IgM result is equivocal; repeat after 1-2 weeks; high index of suspicion with negative initial result warrants testing
- Immunological Assessment: HIV testing if risk factors present; CD4 count in known HIV patients; immune function evaluation in recurrent or severe EBV infections
Fasting Required?
- Fasting Requirement: NO - Fasting is not required for EBV-VCA IgM antibody testing
- Specimen Collection Requirements: Blood sample collected via venipuncture into appropriate serum separator tube; no special collection tube required; room temperature acceptable for transport if completed within 2 hours
- Patient Preparation: No special preparation needed; can eat and drink normally before test; medication schedule does not need adjustment; no fasting period required
- Medications to Avoid: No medications need to be discontinued for this test; antibiotics, antivirals, and other medications do not interfere with antibody detection; continue all routine medications as prescribed
- Timing Considerations: Test can be performed any time of day; optimal timing is 1-2 weeks after symptom onset for best IgM detection; early in illness (first few days) may show false-negative results
- Special Instructions: Inform phlebotomist of acute illness for documentation; provide symptom duration and onset date to assist laboratory interpretation; maintain hydration; no alcohol consumption restrictions
- Specimen Stability: Serum samples stable at room temperature for 24 hours; refrigeration at 2-8°C acceptable for up to 7 days; frozen specimens (-20°C or lower) stable for extended periods if long-term storage needed

How our test process works!